Europe's Clinical Trial Leadership Declines as China Doubles Market Share Over Past Decade
核心洞察
New IQVIA and EFPIA study reveals European Economic Area (搜索)'s share of commercial clinical trials has dropped from 18% to 12%, while China's portion doubled to 18% over the past decade.
The decline translates to 60,000 fewer patients accessing trials in EEA countries and 20,000 fewer spots in EEA-only trials, significantly impacting European patients' access to innovative treatments.
Spain emerges as a bright spot in European clinical research, surpassing Germany in trial numbers through improved facilities, rapid regulatory compliance, and effective public-private collaboration models.
The landscape of global clinical trials has undergone a dramatic shift over the past decade, with Europe experiencing a significant decline in its share of commercially sponsored clinical research while China rapidly ascends to a leadership position.
According to a comprehensive new study conducted by IQVIA and the European Federation of Pharmaceutical Industries and Association (EFPIA), the European Economic Area (搜索)'s (EEA) share of clinical trials has plummeted from 18% to approximately 12% in 2023. Meanwhile, China has emerged as a dominant force, doubling its share to 18% during the same period.
Shifting Global Research Dynamics
The transformation in clinical trial distribution reflects broader changes in the global research ecosystem. North America, traditionally a leading region, has also witnessed a decline, with its share dropping from 26% to 17% in 2023. These shifts occur against a backdrop of a 38% increase in total study starts worldwide.
The impact on European healthcare access is substantial. EFPIA reports that this decline represents 60,000 fewer patients accessing trials involving EEA countries and 20,000 fewer positions available in EEA-only trials, significantly limiting European patients' access to cutting-edge medical treatments.
Areas of Particular Concern
The decline is particularly pronounced in several critical research areas:
- Phase 1 trials
- Cell and gene therapy studies
- Cancer research
- Vaccine development
- Rare disease studies
- Pediatric clinical trials
While the EEA maintains a relatively strong position in large-scale, multi-country studies, even this advantage has eroded, declining from 23% to 19% since 2018.
Regulatory Challenges and Implementation Issues
EFPIA director-general Nathalie Moll points to systemic issues within the European research environment: "European clinical trials are hampered by a slow and fragmented research ecosystem, and current initiatives, at the current pace, are insufficient to stop and reverse a decade of decline."
The EU Clinical Trial Regulation (CTR), implemented in early 2023, has yet to demonstrate significant impact in addressing these challenges. The regulation's slow implementation has failed to adequately address issues such as lengthy set-up times and limited trial access compared to other regions.
China's Competitive Advantage
China's remarkable growth in clinical trial share can be attributed to:
- Streamlined regulatory processes
- Enhanced funding accessibility
- More efficient trial implementation systems
Spain: A Model for Success
In contrast to the broader European trend, Spain has emerged as a success story, overtaking Germany as the country conducting the most clinical trials. This achievement is attributed to:
- Strategic investment in new research facilities
- Swift compliance with CTR requirements
- Successful implementation of commercial/non-commercial trial collaboration models
The path forward for Europe requires significant changes, as Moll emphasizes: "For Europe to be competitive it needs to function as a unified region, not as individual member states, and be supported by policies to attract global research investment."